IP Library Granted Patent US 12,503,428
Granted Patent B2
US 12,503,428 · App. 17/465,929 · Granted Dec 23, 2025

Tunable nitric oxide-releasing macromolecules having multiple nitric oxide donor structures

Inventors: Mark Schoenfisch (Chapel Hill, NC); Yuan Lu (Chapel Hill, NC); Nathan Stasko (Chapel Hill, NC); Jian Bao (Cary, NC)
Assignees: The University of North Carolina at Chapel Hill; Ligand Pharmaceuticals Incorporated
C07C281/20A61K31/655C07C247/10C07C291/02Y10T428/2982
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,503,428
App. No.
17/465,929
Granted
Dec 23, 2025
Kind
B2
Abstract

Provided here are nitric oxide-releasing compounds that include at least two different NO donor functional groups of the same class. In some embodiments, such nitric oxide-releasing compounds are macromolecules such as dendrimer and co-condensed silica. Pharmaceutical compositions, wound dressings, kits and methods of treatments are also provided herein.

Claims (16)

1 . A nitric oxide-releasing macromolecule comprising

at least two different NO donor structures of the same class,

wherein the at least two different NO donor structures are each nitrosothiol donors.

2 . The nitric oxide-releasing macromolecule of claim 1 , wherein the at least two different NO donor structures have different nitric oxide release kinetics.

3 . The nitric oxide-releasing macromolecule of claim 1 , wherein the nitric oxide-releasing macromolecule comprises a dendrimer.

4 . The nitric oxide-releasing macromolecule of claim 3 , wherein the dendrimer comprises at least one of a polypropyleneimine dendrimer; a polyamidoamine (PAMAM) dendrimer; a polyarylether dendrimer; a polypeptide dendrimer; a polyamide dendrimer; a dendritic polyglycerol; and a triazine dendrimer.

5 . The nitric oxide-releasing macromolecule of claim 1 , wherein the nitric oxide-releasing macromolecule comprises co-condensed silica.

6 . The nitric oxide-releasing macromolecule of claim 5 , wherein the silica is present as particles having a mean particle size of less than 10 μm.

7 . A pharmaceutical composition comprising the nitric oxide-releasing macromolecule of claim 1 , at least one excipient and, optionally, at least one additional therapeutic agent.

8 . A kit comprising at least two pharmaceutical compositions of claim 7 .

9 . A wound dressing comprising a polymer matrix and the NO releasing macromolecule of claim 1 .

10 . A kit comprising at least two wound dressings of claim 9 .

11 . A method of treating a dermatological condition, comprising topically administering the NO releasing macromolecule of claim 1 in an amount effective to actively promote healing of a wound associated with the dermatological condition.

12 . The method of claim 11 , wherein the dermatological condition comprises at least one of a wound, microbial infection and inflammation.

13 . The method of claim 11 , wherein the dermatological condition comprises acne.

14 . The nitric oxide-releasing macromolecule of claim 1 , wherein the at least two different NO donor structures are S-nitrosothiols.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2025
From: LNHC, INC.
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 071481/0040 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2024
From: NOVAN, INC.
To: LNHC, INC.
Reel/Frame 066350/0942 →